Novel Molecular Targets Participating in Myocardial Ischemia-Reperfusion Injury and Cardioprotection

Abstract

Worldwide morbidity and mortality from acute myocardial infarction (AMI) and related heart failure remain high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical treatment at present, collateral myocardial ischemia-reperfusion injury (MIRI) and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated bio-methodology in order to bring the poorly understood interrelationship among pro- and anti-MIRI participant molecules up to date, as well as to identify findings that may facilitate the further investigation of novel targets.

RP105 plays a cardioprotective role in myocardial ischemia reperfusion injury by regulating the Toll‑like receptor 2/4 signaling pathways

“…Previous studies have shown that the prevention and treatment of Miri depends on the following features: i) Simply targeting sham, control sham group; i/r, ischemic and reperfusion; ad-r, ad-rP105 group; ad-r-sirna, ad-rP105-sirna group; ad-G-sirna, ad-eGFP-sirna group; Tlr2/4, Toll-like receptor 2/4; TnF-α, tumor necrosis factor; il-6, interleukin 6; Md2, myeloid differentiation protein 2; iP, immunoprecipitation. the protective gene or harmful gene; ii) interfering with the expression of a single gene to play a comprehensive role in multiple pathogenic processes; or iii) modulating the expression of target genes via non-coding rnas (27,28). although these strategies provide novel ways to alleviate Miri, the clinical effect is still unsatisfactory (22,24,(29)(30)(31).…”

Melatonin elicits protective effects on OGD/R‑insulted H9c2 cells by activating PGC‑1α/Nrf2 signaling

“…cardiovascular diseases (cVds) are a common threat to human health and were the leading cause of human mortality between 2009 and 2011 worldwide (1,2). Ischemic heart disease, which accounts for a large subset of cVds, leads to hypoxia and, ultimately, cardiomyocyte death (3). Timely reperfusion is the main therapeutic strategy to resuscitate the ischemic or hypoxic myocardium (4).…”

Ways to improve the results of surgical treatment of patients with multiple valve correction in combination with coronary pathology

“…Набуті вади серця На сьогодні однією з найважливіших проблем у серцево-судинній хірургії, що потребує подальшого дослідження, є забезпечення адекватного інтраопераційного захисту міокарда. Виділяють декілька різноманітних підходів проведення захисту міокарда, які мають свої переваги й недоліки [3,4]. Не існує єдиного, загальновизнаного протоколу при корекції поєднання багатоклапаного ураження з ІХС.…”